During Dr. Nader's five-year tenure as president and chief executive officer, his focus on value creation has significantly contributed to more than ten-fold increase in the company's market capitalization.About NPS Pharmaceuticals NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (U.S.)/Revestive® (EU) (teduglutide [rDNA origin]) for injection is approved for adult Short Bowel Syndrome (SBS) patients who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism and submitted its Biologic License Application to the U.S. Food and Drug Administration in October 2013. NPS’ earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin. Additional information about NPS is available through its corporate website, http://www.npsp.com. Disclosure notice Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on the company's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward looking statements include, but are not limited to, statements concerning the company’s future financial performance and plans for the commercialization of its products. Risks associated to the company's business include, but are not limited to, the risks associated with any failure by the company to successfully commercialize Gattex (teduglutide [rDNA origin]) for injection, including the risk that physicians and patients may not see the advantages of Gattex and may therefore be reluctant to utilize the product, the risk that private and public payers may be reluctant to cover or provide reimbursement for Gattex, risks related to regulatory approvals for Natpara (recombinant human parathyroid hormone 1-84 (rhPTH 1-84)), the risks associated with the company's strategy, global macroeconomic conditions, the impact of changes in management or staff levels, the effect of legislation effecting healthcare reform in the United States, as well as other risk factors described in the company's periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Form 10-Qs. All information in this press release is as of the date of this release and NPS undertakes no duty to update this information, whether as a result of new information, future events or otherwise.
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has received the Ernst & Young National Entrepreneur Of The Year ® 2013 Award in the Life Sciences category. This award is regarded as the world’s most prestigious business award for entrepreneurs. Dr. Nader was honored at an awards gala, the culminating event of the EY Strategic Growth Forum ®, on November 16 in Palm Springs, California. “It’s an honor and a privilege to receive the Ernst & Young National Entrepreneur Of The Year award,” said Dr. Nader. “This wouldn’t be possible without the unwavering dedication and support of the entire NPS team. I look forward to keeping the entrepreneurial spirit alive at NPS as we continue to work to bring innovative therapeutics to patients suffering from rare diseases around the world.” Dr. Nader joined NPS in 2006 and was appointed president and chief executive officer in March 2008. He led the company’s transformation into a global commercial-stage biopharmaceutical company focused on bringing innovative treatments to patients with rare diseases. During his tenure, Dr. Nader created a values-driven culture-by-design that contributed to NPS being named as one of the top 100 companies to work for in New Jersey for two consecutive years. Earlier this year, NPS launched Gattex® (teduglutide [rDNA Origin]) for injection, its first medication approved by the U.S. Food and Drug Administration (FDA) and the European Commission. In March, Dr. Nader established NPS as a global commercial rare disease company by reacquiring the worldwide rights to its two lead drugs from Takeda GmbH. In October, the company submitted its Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its second orphan product Natpara® (recombinant human parathyroid hormone 1-84, rhPTH(1-84)) for the treatment of hypoparathyroidism.